CellCentric is a startup based in the United Kingdom, 2 tracked investors.
CellCentric is a company headquartered in the United Kingdom. Brouky records 2 investors associated with the company.
CellCentric is a clinical-stage biotechnology company focused on developing inobrodib, a first-in-class oral p300/CBP inhibitor for treating specific cancers such as multiple myeloma, prostate cancer, and other hematological malignancies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.